{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Prostate+Gland&page=3",
    "query": {
      "condition": "Metastatic Malignant Neoplasm in the Prostate Gland",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 90,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Prostate+Gland&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Malignant+Neoplasm+in+the+Prostate+Gland&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T14:13:36.558Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04424641",
      "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumor(s)",
        "Prostate Cancer",
        "Esophageal Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "Squamous Cell Carcinoma of Head and Neck (SCCHN)",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Bladder Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-07-15",
      "completion_date": "2021-10-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04424641"
    },
    {
      "nct_id": "NCT01624220",
      "title": "A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Tumor"
      ],
      "interventions": [
        {
          "name": "Spinal SBRT (Standard Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Spinal SBRT (Higher Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Gold Seed Implantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2012-08-03",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624220"
    },
    {
      "nct_id": "NCT04931823",
      "title": "Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "CPO-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conjupro Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2021-03-24",
      "completion_date": "2024-08-26",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Las Vegas, Nevada + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Lyndhurst",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04931823"
    },
    {
      "nct_id": "NCT03896984",
      "title": "Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "Radium-223 (Xofigo, BAY88-8223)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 346,
      "start_date": "2019-03-18",
      "completion_date": "2020-12-14",
      "has_results": false,
      "last_update_posted_date": "2021-12-29",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896984"
    },
    {
      "nct_id": "NCT03217747",
      "title": "Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Castration-Resistant Prostate Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Prostate Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "Refractory Malignant Solid Neoplasm",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Ivuxolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Utomilumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2017-08-02",
      "completion_date": "2026-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03217747"
    },
    {
      "nct_id": "NCT05924672",
      "title": "Efficacy of Ra-223 in PSMA PET Optimally Selected Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Radium-223",
          "type": "DRUG"
        },
        {
          "name": "PSMA Positron Emission Tomography (PET) Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Technetium Tc 99M Medronate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2024-08-30",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05924672"
    },
    {
      "nct_id": "NCT04071236",
      "title": "Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Metastatic Malignant Neoplasm in the Lymph Nodes",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Peposertib",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radium Ra 223 Dichloride",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2020-10-14",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 32,
      "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 24 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04071236"
    },
    {
      "nct_id": "NCT00045006",
      "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045006"
    },
    {
      "nct_id": "NCT07690579",
      "title": "Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer",
        "Prostate Cancer Recurrent",
        "Prostate Metastases"
      ],
      "interventions": [
        {
          "name": "Questionnaires",
          "type": "OTHER"
        },
        {
          "name": "Medical Record Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 350,
      "start_date": "2026-03-31",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07690579"
    },
    {
      "nct_id": "NCT04604158",
      "title": "Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Cancer Metastatic",
        "Neoplasms",
        "Breast Cancer",
        "Lung Cancer",
        "Glioblastoma",
        "Prostate Cancer",
        "Gynecologic Cancer",
        "Colorectal Cancer",
        "Sarcoma",
        "Kidney Cancer",
        "Bladder Cancer",
        "Lymphoma",
        "Leukemia",
        "Head and Neck Cancer",
        "Pancreas Cancer",
        "Multiple Myeloma",
        "Anxiety",
        "Social Isolation",
        "Stress",
        "Loneliness",
        "Melanoma",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Elly Mobile Phone Application",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Gillian Gresham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2020-12-02",
      "completion_date": "2024-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-14T14:13:36.558Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04604158"
    }
  ]
}